2017 ASCO REVIEW
A Phase Ib Study of Isatuximab plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)
Learning Objectives:
- Review the options for treatment of relapsed myeloma.
- Discuss the importance of immunotherapy in myeloma.
- Outline the potential role of the novel agent Isatuximab in myeloma.
Learning Objectives:
- Review high impact phase I studies presented at the ASCO 2017 meeting
- Discuss mechanism of action of novel agents
- Discuss toxicities and efficacy in different tumor types.
Ramesh Ramanathan, M.D.
Professor of Medicine, Mayo College of Medicine
Senior Associate Consultant, Hematology Medical Oncology
Mayo Clinic
Phoenix, Arizona
________________________________________________________________________
Results of the SIMPLIFY 1 Trial: Momelotinib vs Ruxolitinib in Myelofibrosis
Learning Objectives:
- Identify the burden of anemia in myelofibrosis
- Review the outcome of the SIMPLIFY1 trial, and role of momelotinib in MF
Ruben Mesa, M.D.
Professor of Medicine, Mayo College of Medicine
Chair, Division of Hematology Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Chair, Arizona Cancer Coalition
Consultant, Hematology Medical Oncology
Mayo Clinic
Phoenix, Arizona
LOCATION Phoenix campus: WAUGH AUDITORIUM-Side A / Scottsdale campus: CRB 3-011 and MCS 3-358E
to record attendance and to ensure you receive CME credit for your attendance.
NOTE: Attendees must be present to receive code.
ADDITIONAL INFORMATION Light refreshments will be served on the Phoenix campus only.
ARCHIVED PRESENTATIONS Located in Arizona Cancer Center Grand Rounds video library at http://videoexchange.mayo.edu.